BioNTech SE
Stocks making the biggest moves midday: Visa, Smartsheet, JD.com and more
Check out the companies making headlines in midday trading: Visa — Shares dropped nearly 4% following a Bloomberg report that the Justice Department is preparing to file an antitrust lawsuit against the credit card network and payments processor. Smartsheet — Shares surged more than 6% after Blackstone and Vista Equity Partners agreed to buy the […]
Read MoreStocks making the biggest moves premarket: Visa, Starbucks, Salesforce, Lowe’s and more
Check out the companies making headlines in premarket trading: Thor Industries — Shares dropped 2% after the RV maker issued disappointing fiscal-year earnings guidance. The company expects earnings per share to range between $4 and $5, well below a StreetAccount estimate of $6.27 per share. Arlo Technologies — The security systems company popped 3% after […]
Read MoreHealthy Returns: The race to develop combination shots targeting Covid, flu is heating up
New vaccine COMIRNATY® (Covid-19 Vaccine, mRNA) by Pfizer, available at CVS Pharmacy in Eagle Rock, California. Irfan Khan | Los Angeles Times | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! […]
Read MoreModerna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 […]
Read MorePfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its […]
Read MorePfizer shares fall as 2024 revenue and profit forecast disappoints
Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion. The company expects 2024 revenue of $58.5 billion […]
Read MorePfizer’s combination Covid, flu vaccine will move to final-stage trial after positive data
CFOTO | Future Publishing | Getty Images Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. That moves the pharmaceutical giant and its German partner BioNTech one step closer to […]
Read MoreStocks creating the greatest moves midday: Lululemon, Pfizer, News Corp, Charles Schwab and extra
Examine out the businesses producing the greatest moves midday. Lululemon — Shares of the athleisure apparel business surged much more than 10% right after S & P Dow Jones Indices declared that the firm’s stock will be included to the S & P 500 on Wednesday. Lululemon will replace Activision Blizzard following the completion of […]
Read MoreModerna combination Covid, flu vaccine moves to final stage trial after positive data
Artur Widak | Nurphoto | Getty Images Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study. The biotech company hopes its shot, mRNA-1083, can win approval from […]
Read More